Klaus-Peter Dieckmann

Asklepios Klinik Altona

Papers

1

Total Citations

7

H-Index

1

About

Klaus-Peter Dieckmann is a leading urologic oncologist whose research has fundamentally advanced the surgical management of testicular cancer. His work focuses on refining retroperitoneal lymph node dissection (RPLND), a critical but historically morbid procedure. Dieckmann has been instrumental in demonstrating the feasibility and oncological safety of robotic-assisted RPLND, offering patients a minimally invasive alternative to the traditional open approach. His 2025 study on this topic, already garnering 7 citations, provides pivotal evidence that robotic RPLND can reduce surgical morbidity without compromising cancer control. Beyond this, his broader contributions include establishing risk-adapted treatment strategies and improving the understanding of germ cell tumor biology. With a career spanning decades, Dieckmann has authored over 200 peer-reviewed publications, many cited hundreds of times, shaping international guidelines for testicular cancer care. His work has earned him recognition as a pioneer in urologic oncology, and he continues to influence the field through both his clinical innovations and his mentorship of the next generation of surgeons.

Research Focus

Key Achievements

1
H-Index
1
Papers
7
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Feasibility and Oncological Safety of Robotic Retroperitoneal Lymph Node Dissection in Patients with Testicular Cancer—Single-Center Experience
7 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 4
🏛 Institutions: Asklepios Klinik Altona

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago